tradingkey.logo

Caris Life Sciences Inc

CAI
查看詳細走勢圖
22.000USD
+0.750+3.53%
收盤 02/06, 16:00美東報價延遲15分鐘
6.21B總市值
虧損本益比TTM

Caris Life Sciences Inc

22.000
+0.750+3.53%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+3.53%

5天

-5.01%

1月

-23.56%

6月

-23.05%

今年開始到現在

-18.46%

1年

0.00%

查看詳細走勢圖

TradingKey Caris Life Sciences Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Caris Life Sciences Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值低估,在醫療設備與耗材行業排名58/205位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為37.89。中期看,股價處於下降通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Caris Life Sciences Inc評分

相關信息

行業排名
58 / 205
全市場排名
162 / 4521
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

Caris Life Sciences Inc亮點

亮點風險
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
估值高估
公司最新PE估值-4.36,處於3年歷史高位
喬治·索羅斯持倉
明星投資者喬治·索羅斯持倉,最新持倉55.65K股

分析師目標

基於 9 分析師
買入
評級
37.889
目標均價
+73.48%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Caris Life Sciences Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Caris Life Sciences Inc簡介

Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
公司代碼CAI
公司Caris Life Sciences Inc
CEOHalbert (David Dean)
網址https://www.carislifesciences.com/
KeyAI